Arvinas to Present at the 42nd Annual Goldman Sachs Global Healthcare Conference
Arvinas, a clinical-stage biotechnology company (Nasdaq: ARVN), announced participation in the 42nd Annual Goldman Sachs Global Healthcare Conference on June 10 at 10:30 a.m. ET. Chief Medical Officer Ron Peck, M.D., and Chief Financial Officer Sean Cassidy will engage in a fireside chat. The event will be available via live audio webcast on Arvinas’ website, with a replay accessible for 30 days. Arvinas focuses on developing therapies that target and degrade disease-causing proteins using its innovative PROTAC® technology.
- None.
- None.
NEW HAVEN, Conn., June 03, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ron Peck, M.D., Chief Medical Officer, and Sean Cassidy, Chief Financial Officer, will participate in a fireside chat at the 42nd Annual Goldman Sachs Global Healthcare Conference on Thursday, June 10 at 10:30 a.m. ET.
A live audio webcast of the presentation will be available here and on Arvinas’ website at www.arvinas.com. A replay of the webcast will be archived on Arvinas’ website for 30 days following the presentation.
About Arvinas
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and “undruggable” targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com.
Contacts for Arvinas
Investors
Will O’Connor, Stern Investor Relations
ir@arvinas.com
Media
Kirsten Owens, Arvinas Communications
kirsten.owens@arvinas.com
FAQ
When is Arvinas participating in the Goldman Sachs Global Healthcare Conference?
Who from Arvinas will be speaking at the Goldman Sachs Global Healthcare Conference?
How can I listen to the Arvinas presentation at the conference?
What is the focus of Arvinas' research and development?
What clinical programs are currently in development at Arvinas?
